Metabolism: Effects of sugar-lowering drugs on dementia risk

Dementia is more common in people with type 2 diabetes, but little is known about the effects of sugar-lowering drugs on the associationA study published recently in The Journal of Metabolic Diseases, Metabolism-Clinical and Id, was published to assess the effects of various sugar-lowering drugs on dementia risk in people with type 2 diabetesresearchers searched the Central Registry (CENTRAL) and ClinicalTrials.gov databases of PubMed, Embase, Cochrane control trials, including nine sugar-lowering drugsThe researchers combined data through a web-based meta-analysis and meta-analysisthe analysis selected a total of 9 studies, a total of 530,355 subjects for online meta-analysis, and 17 studies a total of 1258879 subjects were selected for meta-analysisDue to the lack of data, the analysis excluded glucagon-like peptide 1 (GLP-1) analogues and sodium-dependent glucose transport protein 2 (SGLT-2) inhibitorsCompared to non-sugar-lowering drug therapy, the risk of reduced risk of dementia was associated with the use of dipeptide-based peptidease-4 (DPP-4) inhibitors, metformin, thuphynosin, and sulfonylin (DPP-4 inhibitors had a risk ratio of 0.54; 95% confidence interval of 0.38-0.74, metformin) was usedThe HR for tybieth is 0.75; 95% CI is 0.63-0.86; the HR for sulfonylamide is 0.85; the 95% CI is 0.73-0.98; the HR of tatrandrexbin is 0.70; and 95% CI is 0.55-0.89)However, the node decomposition analysis showed inconsistencies in the direct and indirect estimates of sulfonylurea drugs (P-0.042)Compared to insulin, DPP-4 inhibitors, metformin, metformin, sulphate and sulfonylquina have a significant impact on the risk of dementia in diabetic patients (HR 0.35; 95% CI 0.20-0.59, HR 0.48, HR 0.48 ;95% CI is 0.30-0.77, HR is 0.45; 95% CI is 0.29-0.73; HR is 0.55; 95% CI is 0.34-0.88)DPP-4 inhibitors also showed a protective effect on Alzheimer's risk compared to those treated without a sugar-lowering drug (HR 0.48; 95% CI 0.25-0.92)Meta-metformin and DPP-4 inhibitor syltopsare had a protective effect on dementia risk (HR 0.86; 95% CI 0.74-1.00; HR 0.65; 95% CI 0.55-0.76)Further analysis showed that insulin was associated with an increased risk of Alzheimer's dementia (HR 1.60; 95% CI 1.12-3.26)Only two case-control studies mentioned GLP-1 analogues and SGLT-2 inhibitors, and the combined OR found no evidence of dementia (GLP-1 analogues: 0.71; 95% CI 0.46-1.10 and SGLT-2 inhibitors: 0.74; 95% CI 0.47-1.15)the analysis showed that people with type 2 diabetes who received DPP-4 inhibitors had the lowest risk of developing dementia, followed by those treated with metformin and diazepam, with the highest risk of developing the disease with insulin therapyIn order to pay more and more attention to the protective effects of dementia, further specific clinical studies are needed to assess the effects of GLP-1 analogues and SGLT-2 inhibitors on dementia risk